

A novel *MYOC* heterozygous mutation identified in a Chinese Uygur pedigree with primary open-angle glaucoma

Su-ping Cai,¹ Paerheti Muhemaiti,² Yan Yin,³ Hongbo Cheng,¹ A. Di Ya,² Maliyamu Keyimu,² Xu Cao,³ Ning Fan,¹ Liqiong Jiang,¹ Naihong Yan,³ Xiaomin Zhou,³ Yun Wang,¹ Xuyang Liu¹

(The first two authors contributed equally to the work)

¹Shenzhen Eye Hospital, Jinan University, Shenzhen, P.R.China; ²A Di Ya Eye Hospital, Wulumuqi, Xinjiang, P.R.China; ³Ophthalmic Laboratories, Translational Neuroscience Center, West China Hospital, Sichuan University, P.R.China

Purpose: To characterize the clinical features of a Chinese Uygur pedigree with primary open-angle glaucoma (POAG) and to identify mutations in two candidate genes, trabecular meshwork inducible glucocorticoid response (*MYOC*/*TIGR*) and human dioxin-inducible cytochrome P450 (*CYP1B1*).

Methods: Twenty one members from a Chinese Uygur family of four generations were included in the study. All participants underwent complete ophthalmologic examinations. Five were diagnosed as POAG, four as glaucoma suspects, and the rest were asymptomatic. Molecular genetic analysis was performed on all subjects included in the study. All exons of *CYP1B1* and *MYOC* were amplified by polymerase chain reaction (PCR), sequenced and compared with a reference database. The variations detected were evaluated in available family members as well as 102 normal controls. Possible changes in structure and function of the protein induced by amino acid variance were predicted by bioinformatics analysis.

Results: Elevated intraocular pressure and late-stage glaucomatous cupping of the optic disc were found in five patients of this family. A novel heterozygous missense mutation c.1151 A>G in exon 3 of *MYOC* was found in all five patients diagnosed as POAG and four glaucoma suspects, but not in the rest of the family members and 102 normal controls. This mutation caused an amino acid substitution of aspartic acid to glycine at position 384 (p. D384G) of the *MYOC* protein. This substitution may cause structural and functional changes of the protein based on bioinformatics analysis. No mutations were found in *CYP1B1*.

Conclusions: Our study suggests that the novel mutation D384G of *MYOC* is likely responsible for the pathogenesis of POAG in this pedigree.

Glaucoma is one of the leading causes of irreversible blindness in the world and is a neurodegenerative disorder characterized by progressive loss of retinal ganglion cells that results in the excavation of the optic disc and gradual constriction of visual field [1]. It is usually associated with elevation of intraocular pressure (IOP) [2]. The most prevalent form of glaucoma is primary open-angle glaucoma (POAG; OMIM 137760) [3]. POAG has two forms: juvenile and adult onset, with the latter most commonly seen. Juvenile open-angle glaucoma (JOAG) may manifest clinically between the ages of 3 and 30 [4,5], while adult POAG usually occurs after the age of 40 [6,7]. Although the exact mechanisms of POAG are not fully understood, it is generally accepted that genetic factors play an important role in its pathogenesis. About 30%–56% of patients with glaucoma or ocular hypertension (OHT) have a positive family history; first-degree relatives of POAG patients are seven to ten times more likely to have POAG [8,9]. Four genes, including trabecular meshwork inducible glucocorticoid response (*MYOC*), human dioxin-inducible

cytochrome P450 (*CYP1B1*), optineurin (*OPTN*), and *WD* repeat domain 36 (*WDR36*), have been identified as glaucoma-associated genes [10]. Up to date, more than 70 mutations have been detected in *MYOC*, the first identified POAG causing gene, worldwide [11,12]. About 90% of the mutations were located in exon 3 of *MYOC* where the olfactomedin-like domain is located [13]. Of particular interest, the *MYOC* gene has been reported to interact with *CYP1B1* through a digenic mechanism, leading to JOAG [14–16]. Both *MYOC* and *CYP1B1* consist of three exons, but in *CYP1B1*, only exon 2 and 3 encode the protein. In this study, both *MYOC* (three exons) and *CYP1B1* (exon 2 and 3) genes were analyzed.

METHODS

Family recruitment and clinical examination: A four-generation pedigree with POAG (Figure 1) was recruited from A Di Ya Eye Hospital (Wulumuqi, Xinjiang, P. R. China). No consanguineous marriage was noticed in the family. Twenty one members of the family underwent complete ophthalmologic examinations including slit-lamp biomicroscopy, gonioscopy, IOP measurement (Canon TX-F Non-contact tonometer; Canon Inc., Tokyo, Japan), fundus

Correspondence to: Dr. Xuyang Liu, Shenzhen Eye Hospital, Jinan University, Shenzhen, 518000, P. R. China; Phone: (86) 755-23959546; email: xliu1213@126.com




Figure 1. Pedigrees of the Chinese Uygur family with primary open-angle glaucoma. Filled squares and circles are affected males and females, respectively. Small filled square in the middle of the circle or square indicates the carrier. Arrowhead indicates the proband. The asterisks indicate the individuals who had undergone clinical examination. Molecular analyses were done in all individuals marked with asterisks.

examination and visual field test. All individuals in the control group were healthy and with no history of other familial inherited diseases. The study was approved by the Medical Ethics Committee of the Shenzhen Eye Hospital of Jinan University in Guangdong Province, Shenzhen. Informed consent was obtained from all participants according to the principles of Declaration of Helsinki. All subjects were clinically evaluated by glaucoma specialists.

Mutation screening and sequence analysis: Genomic DNA was extracted from 200 μ l venous blood using a Qiamp Blood Kit (Qiagen, Hilden, Germany). All the procedures were performed according to the manufacturer's instructions. DNA integrity was detected by 1% agarose gel electrophoresis. Intronic primers flanking the exons were designed (Table 1) based on gene sequences of *MYOC* (GenBank AF001620) and *CYP1B1* (GenBank U56438), and synthesized by Invitrogen (Carlsbad, CA). Exons of *MYOC* and *CYP1B1* were amplified by PCR using the designed forward and reverse primers. PCR amplification was conducted in a MyCycler thermocycler (Bio-Rad, Hercules, CA). The 30 μ l PCR reaction mixtures included 30–40 ng genomic DNA, 1.0 μ M of each of the forward and reverse primers, and 15 μ l of 2 \times Taq Master Mix (including 1 \times PCR buffer, 2.5 mM MgCl₂, 0.3 mM of each of dNTPs, 1.5 U Pfu DNA polymerase). All reagents used in this procedure were purchased from SinoBio Biltech Co. Ltd, Shanghai, China. The cycling conditions included an initial denaturation at 95 $^{\circ}$ C for 5 min, followed by 35 cycles of denaturation at 95 $^{\circ}$ C for 30 s, annealing at 58.4 $^{\circ}$ C for 30 s (the second exon of *CYP1B1* at 55 $^{\circ}$ C), extension at 72 $^{\circ}$ C for 60 s (the second exon of *MYOC* for 30 s and the rest for 90 s), and then a final extension at 72 $^{\circ}$ C for 5 min. The amplified products were purified with a cycle-pure kit (OMEGA; Bio-

Tek, Doraville, GA) and sequenced on the ABI 3730XL automated DNA sequencer (Applied Biosystems, Foster City, CA). Sequence data were compared pair-wise with the published *MYOC* and *CYP1B1* sequences. Mutation was named according to the nomenclature recommended by the Human Genomic Variation Society (HGVS).

Bioinformatics analysis: The Clustalw tool was used to align the protein sequences among eight different species. The possible functional impact of an amino acid change was predicted by Polyphen and Sorting Intolerant From Tolerant (SIFT). Garnier-Osguthorpe-Robson (GOR IV) software was used to predict the effect of the mutation on the secondary structure of MYOC [17]. This method infers the secondary structure of a sequence by calculating the probability for each of the four structure classes (helix, sheet, turn, and loop) based on the central residue and its neighbors from the calculated matrices.

RESULTS

Clinical findings of the pedigree: Five out of twenty one members examined in this four-generation family were found to have elevated intraocular pressure and late-stage glaucomatous cupping of the optic disc. Four suspects were found to have elevated intraocular pressure without characteristic glaucomatous optic disc changes (Table 2, Figure 2). The proband (III-8, a thirty-three-year-old female) was diagnosed as JOAG in both eyes at the age of 28, with elevated IOPs (42 mmHg OU), open anterior chamber angle, enlarged cup disc ratio of 0.95/0.8 (OD/OS). No systemic disorders were found. Trabeculectomy was performed for both eyes at the age of 30. Three years later, IOP measured 15–18 mmHg OS. The visual acuity in the right eye worsened

TABLE 1. PRIMERS USED IN PCR FOR AMPLIFICATION OF *MYOC* AND *CYP1B1*.

Exons	Primer sequence (forward/reverse)	Product size (bp)
<i>MYOC</i> 1	PF 5'-CCAAACAGACTTCTGGAAGG-3'	904
	PR 5'-TAGCAGGTCACTACGAGCC-3'	
<i>MYOC</i> 2	PF 5'-TGTCATCCTCAACATAGTCA-3'	351
	PR 5'-TTCTGTTCTCTTCTCCTC-3'	
<i>MYOC</i> 3	PF 5'-CCAGGGCTGTCACATCTACT-3'	933
	PR 5'-CATCTCCTTCTGCCATTGC-3'	
<i>CYP1B1</i> 2	PF 5'-CATTTCTCCAGAGAGTCAGC-3'	1260
	PR 5'-GCTTGCAAACCTCAGCATATTC-3'	
<i>CYP1B1</i> 3	PF 5'-ACCCAATGGAAAAGTCAGCC-3'	927
	PR 5'-GCTTGCCTCTTGCTTCTTATT-3'	

TABLE 2. PATIENT DATA FROM THIS POAG PEDIGREE.

Patient	Sex	Age at study (years)	Diagnosis age (years)	Maximal IOP (mmHg)	C/D ratio	Operation age (years)
II-2	female	60	55	48~50 (ou)	1.0/1.0	—
III-2	female	40	40	42 (od), 50 (os)	0.95/1.0	—
III-8	female	33	28	42 (ou)	0.95/0.8	30
III-12	female	29	27	32 (od), 35 (os)	0.8/0.8	—
III-13	male	25	25	52 (ou)	1.0/1.0	—
IV:1	female	22	22	21 (od), 24 (os)	0.4/0.4	—
IV:2	male	20	20	24 (od), 26 (os)	0.4/0.4	—
IV:9,	female	9	9	25 (od), 28 (os)	0.4/0.4	—
IV:13	male	4	4	25 (od), 25 (os)	—*	—

* indicates that C/D ratio was not able to be obtained since the child was not cooperative with exam.

to no light perception. The proband's mother (II-2) was diagnosed as POAG at the age of 55. She recalled that she had reduced vision since her early thirties and became totally blind at her early forties. Her IOPs measured 48~50 mmHg OU with the cup/disc ratio of 1.0 OU. Both eyes of the proband's uncle (II-5) became blind when he was in his early 40s. Since his blood sample was not available, this patient was not included in the study. The proband's older sister (III-2) was diagnosed as JOAG at the age of 40 with IOPs of 42/50 mmHg (OD/OS). Funduscopy revealed a glaucomatous excavation and atrophy of the optic disc in both eyes with a cup-disc ratio of 0.95/1.0 (OD/OS). She recalled that she had reduced vision in her early thirties. Patient III-12 was diagnosed as JOAG in both eyes at the age of 27. Her IOPs was 35 mmHg OS and 32 mmHg OD. A cup/disc ratio of 0.8/0.8 OU was noticed in the patient (Figure 2). Patient III-13 was diagnosed as JOAG at the age of 25 with the visual acuity of light perception OD, and hand motions OS. His maximal IOPs measured 52 mmHg OU. Funduscopy revealed optic nerve atrophy in both eyes with a cup-disc ratio of 1.0. Patient IV:1, a 22-year-old female, was a glaucoma suspect. Her IOP measured 21/24mmHg (OD/OS) and no defect in optic disc and visual field was noticed. Her

20-year-old younger brother (IV:2) had elevated IOP of 24 mmHg OD and 26 mmHg OS with normal optic disc and visual field. Two young family members, one was a 9-year-old girl (IV:9), the other was a 4-year-old boy (IV:13), were found to have elevated IOP. Possible optic disc damage was found in the 9-year-old girl but was not found in the 4-year-old boy. The visual field results of both of them were unreliable. No ocular abnormalities were found in the rest of the family numbers.

MYOC and CYP1B1 mutation identification and analysis: Sequence analysis of *MYOC* revealed a heterozygous missense mutation, c.1151 A>G (p. D384G), in exon 3 of all five patients, four glaucoma suspects. No such mutation was detected in other asymptomatic members of the family and 102 normal control subjects included in this study (Figure 3). No other mutations were identified in this gene and in *CYP1B1*.

Bioinformatic analysis: The mutation c.1151 A>G in exon 3 of *MYOC* would result in replacement of aspartic acid by glycine. Aspartic acid in 384 was highly conserved for *MYOC* based on analysis of orthologs from eight different species using the online [Clustalw](#) tool (Figure 4). The pD384G




Figure 2. Fundography of glaucoma patients and suspects. Fundography of a glaucoma patient III-12 (A, B), two suspects: IV:9, a 9-year-old (C, D), and IV:13, a 4-year-old (E, F).




Figure 3. Sequencing results of the *MYOC* gene. **A:** A heterozygous A to G transversion at codon 384 in one patient from the family (red arrow). **B:** Wild type sequence from an unaffected member.

mutation of *MYOC* was predicted to be “probably damaging” by *Polyphen* with a score of 2.189 and “affect protein function” by *SIFT* with a score of 0.00, which indicated that protein function was affected by amino acid changes (score <0.05 indicating that the amino-acid change may affect the protein function). The results for secondary structure prediction by the *GORIV* method suggested that the mutant *MYOC* 384G replace two β sheet “E”s with two coil “C”s at amino acid 384 and 385 (Figure 5).

DISCUSSION

MYOC was the first identified gene associated with pathogenesis of POAG [11]. Previous studies showed that *MYOC* mutations exist in a greater proportion of JOAG and nearly 3% of adult onset POAG patients [18,19]. *MYOC* mutations have been reported in POAG pedigrees from many different ethnic groups [18-36]. In this study, the *MYOC* gene

was screened for mutations in a four-generation Uyghur, an ethnic minority in China, family.

The identified *MYOC* mutations involved in POAG in different ethnic populations include Pro370Leu, Gly367Arg, Arg158Gln, Gly252Arg, Arg272Gly, Asn 450 Tyr, Gln48His and Asp 384 Asn [11,20-26,35-37]. Most *MYOC* mutations were located in exon 3, while some in exon 1 [38]. In this study, an A to G transversion at the second base of codon 384 (in exon 3 of *MYOC*), which resulted in aspartic acid to glycine amino acid substitution, was identified in all affected glaucoma patients (II:2, III:2, III:8, III:12, III:13), and four glaucoma suspects (IV:1, IV:2, IV:9, IV:13), but not in other unaffected members of the family and 102 normal control subjects. The results of *GORIV* suggested that p.D384G lead to a secondary structure change by replacing two β sheet “E”s with two coil “C”s around the aspartic acid residue 384, which might interfere with the correct folding of the protein. The

Homo sapiens	NTETVKA E KEIPGAGYHGQFPYSWGGYTDIDLAV D EAGLWVIYSTDEAKGAI
Macaca fascicularis	NTETVKAQ K KEIPGAGYHGQFPYSWGGYTDIDLAV D ESGLWVIYSTDEAKGAI
Felis catus	NTETVKA E KEIPGAGYHGQFPYSWGGYTDIDLAV D ETGLWVIYSTQEAKGAI
Canis lupus familiaris	TAETVKA E REIPGAGYHGQFPYSWGGYTDIDLAV D ETGLWVIYSTQEAKGAI
Bos taurus	RTETLKA E KEIPGAGYHGQFPYSWGGYTDIDLAV D EIGLWVIYSTEAAKGAI
Oryctolagus cuniculus	NTETVKA E KEIPGAGYRGQFPYSWGGYTDIDLAV D ETGLWVIYSTEARGAI
Mus musculus	DTETVKA E KEIPGAGYHG H FPYAWGGYTDIDLAV D ESGLWVIYSTEAKGAI
Rattus norvegicus	NTETVKA E KEIPGAGYHGQFPYAWGGYTDIDLAV D ESGLWVIYSTEETRGAI

:***:**:* *****:*:**:***** *****: :***

Figure 4. The mutation involved a highly conserved residue. The aspartic acid at position 384 are highly conserved for MYOC, which was demonstrated by analysis of orthologs from eight different species.




Figure 5. The effect of p. D384G on the secondary structure of MYOC using the GORIV method. **A**: The secondary structure of wild type MYOC around the site D384. **B**: The secondary structure of mutant G384 of MYOC of the corresponding region.

MYOC gene mutation exhibited as heterozygous. To date, to the best of our knowledge, this mutation has not been reported in any other ethnic groups. The majority of POAG were juvenile onset in this pedigree since the onset of symptoms occurs before the age of 30 in most patients. Some patients became blind before they came to see glaucoma specialist. This is consistent with previous finding that MYOC mutations exist in a greater proportion of JOAG patients. The D384G mutation of MYOC in this family appears to be the cause of the disease in this family. In this pedigree, all the glaucoma suspects including a 22-year-old female, a 20-year-old male, a 9-year-old girl and 4-year-old boy in the fourth generation were found to harbor this mutation. They were found to have normal optic disc appearance except the 9-year-old girl who may have early stage glaucomatous optic disc. Careful follow up of these individuals will make it possible to identify new patients at the early stage. Early and proper control of their

IOP should help to prevent them from having blindness at young age like the JOAG patients with the same mutation in their family. It should be noted that the Xingjiang (Uyghur) are very sparsely populated. The inhabitants there usually do not come to see the doctors unless they have to or are required to do so since transportation is very inconvenient.

Recently, another gene, *CYP11B1*, has been suggested to modify the glaucoma phenotype [10]. It may act as a modifier of MYOC expression or the two genes may interact via a common pathway [39,40]. We also screened for *CYP11B1* gene, but no mutation was detected.

In summary, this is the first time that D384G mutation was identified in glaucoma patients. This study added a novel mutation to the existing spectrum of MYOC mutations, suggesting that a mutation in MYOC correlated with glaucoma as observed in this family. These results provide pre-symptomatic molecular diagnosis for the members of the

pedigree and are useful for follow-up of the family. All carriers of the family should undergo ophthalmologic surveillance at regular intervals for the rest of their lives.

ACKNOWLEDGMENTS

The authors are deeply grateful to all the family members for their cooperation in this study. This work was supported by grants from the National Nature Science Foundation of China (NNSF 30872830 and 81170851).

REFERENCES

- Quigley HA. Number of people with glaucoma worldwide. *Br J Ophthalmol* 1996; 80:389-93. [PMID: 8695555]
- Merck Manual Home Edition. "Glaucoma". Merck.com. <http://www.merckmanuals.com/home/sec20/ch233/ch233a.html>. Retrieved 2011-01-24.
- Fraser SG. Epidemiology of primary open angle glaucoma. In: Hitchings RA, editors. *Glaucoma*. London: BMJ Publ Group; 2004. P.9-15.
- Ellis OH. The etiology, symptomatology and treatment of juvenile glaucoma. *Am J Ophthalmol* 1948; 31:1589-96. [PMID: 18122120]
- Goldwyn R, Waltman SR, Becker B. Primary open-angle glaucoma in adolescents and young adults. *Arch Ophthalmol* 1970; 84:579-82. [PMID: 5478882]
- Wilson R, Matrone J. Epidemiology of chronic open angle glaucoma. In: Ritch R, Shields BM, Krupin T, editors. *The glaucomas*. 2nd ed. St Louis: Mosby; 1996. p. 753-68.
- Quigley HA. Open-angle glaucoma. *N Engl J Med* 1993; 328:1097-106. [PMID: 8455668]
- Booth A, Churchill A, Anwar R, Menage M, Markham A. The genetics of primary open angle glaucoma. *Br J Ophthalmol* 1997; 81:409-14. [PMID: 9227209]
- Budde WM. Heredity in primary open-angle glaucoma. *Curr Opin Ophthalmol* 2000; 11:101-6. [PMID: 10848214]
- Libby RT, Gould DB, Anderson MG, John SW. Complex Genetics of Glaucoma Susceptibility. *Annu Rev Genomics Hum Genet* 2005; 6:15-44. [PMID: 16124852]
- Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR, Sunden SL, Nishimura D, Clark AF, Nystuen A, Nichols BE, Mackey DA, Ritch R, Kalenak JW, Craven ER, Sheffield VC. Identification of a gene that causes primary open angle glaucoma. *Science* 1997; 275:668-70. [PMID: 9005853]
- <http://www.myocilin.com/variants.php> (accessed June 19,2010).
- Rozsa FW, Shimizu S, Lichter PR, Johnson AT, Othman MI, Scott K, Downs CA, Nguyen TD, Polansky J, Richards JE. GLC1A mutations point to regions of potential functional importance on the TIGR/MYOC protein. *Mol Vis* 1998; 4:20. [PMID: 9772276]
- Vincent AL, Billingsley G, Buys Y, Levin AV, Priston M, Trope G, Williams-Lyn D, Héon E. Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene. *Am J Hum Genet* 2002; 70:448-60. [PMID: 11774072]
- Melki R, Colomb E, Lefort N, Brézin AP, Garchon HJ. CYP1B1 mutations in French patients with early-onset primary open angle glaucoma. *J Med Genet* 2004; 41:647-51. [PMID: 15342693]
- López-Garrido MP, Sánchez-Sánchez F, López-Martínez F, Aroca-Aguilar JD, Blanco-Marchite C, Coca-Prados M, Escribano J. Heterozygous CYP1B1 gene mutations in Spanish patients with primary open-angle glaucoma. *Mol Vis* 2006; 12:748-55. [PMID: 16862072]
- Garnier J, Gibrat JF, Robson B. GOR method for predicting protein secondary structure from amino acid sequence. *Methods Enzymol* 1996; 266:540-53. [PMID: 8743705]
- Alward WL, Kwon YH, Khanna CL, Johnson AT, Hayreh SS, Zimmerman MB, Narkiewicz J, Andorf JL, Moore PA, Fingert JH, Sheffield VC, Stone EM. Variations in the myocilin gene in patients with open-angle glaucoma. *Arch Ophthalmol* 2002; 120:1189-97. [PMID: 12215093]
- Fingert JH, Héon E, Liebmann JM, Yamamoto T, Craig JE, Rait J, Kawase K, Hoh ST, Buys YM, Dickinson J, Hockey RR, Donna WL, Trope G, Kitazawa Y, Ritch R, Mackey DA, Alward WL, Sheffield VC, Stoned EM. Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. *Hum Mol Genet* 1999; 8:899-905. [PMID: 10196380]
- Ge J, Zhuo Y, Guo Y, Yin W. Gene mutation in patients with primary open-angle glaucoma in a pedigree in China. *Chin Med J (Engl)* 2000; 113:195-7. [PMID: 11775243]
- Faucher M, Anctil JL, Rodrigue MA, Duchesne A, Bergeron D, Blondeau P, Côté G, Dubois S, Bergeron J, Arseneault R, Morissette J, Raymond V, Québec Glaucoma Network. Founder TIGR/myocilin mutations for glaucoma in the Quebec population. *Hum Mol Genet* 2002; 11:2077-90. [PMID: 12189160]
- Kennan AM, Mansergh FC, Fingert JH, Clark T, Ayuso C, Kenna PF, Humphries P, Farrar GJ. A novel Asp380Ala mutation in the GLC1A/myocilin gene in a family with juvenile onset primary open angle glaucoma. *J Med Genet* 1998; 35:957-60. [PMID: 9832047]
- Suzuki Y, Shirato S, Taniguchi F, Ohara K, Nishimaki K, Ohta S. Mutation in TIGR gene in familial primary open angle glaucoma in Japan. *Am J Hum Genet* 1997; 61:1202-4. [PMID: 9345106]
- Mabuchi F, Yamagata Z, Kashiwagi K, Ishijima K, Tang S, Iijima H, Tsukahara S. A sequence change (Arg158Gln) in the leucine zipper-like motif region of the MYOC/TIGR protein. *J Hum Genet* 2001; 46:85-9. [PMID: 11281418]
- Pang CP, Leung YF, Fan B, Baum L, Tong WC, Lee WS, Chua JK, Fan DS, Liu Y, Lam DS. TIGR/MYOC gene sequence alterations in individuals with and without primary open-angle glaucoma. *Invest Ophthalmol Vis Sci* 2002; 43:3231-5. [PMID: 12356829]
- Shimizu S, Lichter PR, Johnson AT, Zhou Z, Higashi M, Gottfredsdottir M, Othman M, Moroi SE, Rozsa FW, Schertzer RM, Clarke MS, Schwartz AL, Downs CA, Vollrath D, Richards JE. Age-dependent prevalence of mutations at the GLC1A locus in primary open-angle glaucoma. *Am J Ophthalmol* 2000; 130:165-77. [PMID: 11004290]
- Taniguchi F, Suzuki Y, Shirato S, Araie M. The Gly367Arg mutation in the myocilin gene causes adult-onset primary open-angle glaucoma. *Jpn J Ophthalmol* 2000; 44:445-8. [PMID: 10974305]
- Mansergh FC, Kenna PF, Ayuso C, Kiang AS, Humphries P, Farrar GJ. Novel Mutations in the TIGR Gene in Early and Late Onset Open Angle Glaucoma. *Hum Mutat* 1998; 11:244-51. [PMID: 9521427]

29. Michels-Rautenstrauss KG, Mardin CY, Budde WM, Liehr T, Polansky J, Nguyen T, Timmerman V, Van Broeckhoven C, Naumann GO, Pfeiffer RA, Rautenstrauss BW. Juvenile open angle glaucoma: fine mapping of the TIGR gene to 1q24.3–q25.2 and mutation analysis. *Hum Genet* 1998; 102:103-6. [PMID: 9490287]
30. Cobb CJ, Scott G, Swingler RJ, Wilson S, Ellis J, MacEwen CJ, McLean WH. Rapid mutation detection by the Transgenomic wave analyser DHPLC identifies MYOC mutations in patients with ocular hypertension and/or open angle glaucoma. *Br J Ophthalmol* 2002; 86:191-5. [PMID: 11815346]
31. Kanagavalli J, Krishnadas SR, Pandaranayaka E, Krishnaswamy S, Sundaresan P. Evaluation and understanding of myocilin mutations in Indian primary open angle glaucoma patients. *Mol Vis* 2003; 9:606-14. [PMID: 14627955]
32. Melki R, Belmouden A, Brézin A, Garchon HJ. Myocilin Analysis by DHPLC in French POAG Patients: Increased Prevalence of Q368X Mutation. *Hum Mutat* 2003; 22:179. [PMID: 12872267]
33. Iliev ME, Bodmer S, Gallati S, Lanz R, Sturmer J, Katsoulis K, Wolf S, Trittibach P, Sarra GM. Glaucoma phenotype in a large Swiss pedigree with the myocilin Gly367Arg mutation. *Eye (Lond)* 2008; 22:880-8. [PMID: 17304254]
34. Chen J, Cai S, Yan N, Liu G, Yu w, Liu X. Sequence Analysis of MYOC and CYP1B1 in a Chinese Pedigree of Primary Open angle Glaucoma. *Mol Vis* 2011; 17:1431-5. [PMID: 21655360]
35. Zhao X, Yang C, Tong Y, Zhang X, Xu L, Li Y. Identification a novel MYOC gene mutation in a Chinese family with juvenile-onset open angle glaucoma. *Mol Vis* 2010; 16:1728-35. [PMID: 20806035]
36. Jia LY, Gong B, Pang CP, Huang Y, Lam DS, Wang N, Yam GH. Correction of the disease phenotype of myocilin-causing glaucoma by a natural osmolyte. *Invest Ophthalmol Vis Sci* 2009; 50:3743-9. [PMID: 19234343]
37. Fan BJ, Leung DY, Wang DY, Gobeil S, Raymond V, Tam PO, Lam DS, Pang CP. Novel myocilin mutation in a Chinese family with juvenile-onset open-angle glaucoma. *Arch Ophthalmol* 2006; 124:102-6. [PMID: 16401791]
38. Tamm ER, Russell P. The role of myocilin/TIGR in glaucoma: results of the Glaucoma Research Foundation catalyst meeting in Berkeley, California, March 2000. *J Glaucoma* 2001; 10:329-39. [PMID: 11558819]
39. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME, Or M, Lewis RA, Ozdemir N, Brice G, Aktan SG, Chevrette L, Coca-Prados M, Sarfarazi M. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. *Am J Hum Genet* 1998; 62:573-84. [PMID: 9497261]
40. Bagiyeva S, Marfany G, Gonzalez-Angulo O, Gonzalez-Duarte R. Mutational screening of CYP1B1 in Turkish PCG families and functional analyses of newly detected mutations. *Mol Vis* 2007; 13:1458-68. [PMID: 17893647]

Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China. The print version of this article was created on 14 July 2012. This reflects all typographical corrections and errata to the article through that date. Details of any changes may be found in the online version of the article.